乳腺癌辅助放疗中下腋窝非计划剂量:切向束与VMAT的剂量学差异
结果显示VMAT并未显著降低腋窝I水平的非计划剂量,VMAT的腋窝I水平V50%更高,但高剂量区无临床相关差异。
要点
- VMAT的腋窝I水平V50%显著高于3DCRT和F-IMRT,非计划剂量未降低。
- 腋窝II水平V50%在所有技术中均较低。
- 高剂量区(V90%及以上)各技术间无临床相关差异。
核心结论
- 全乳放疗采用VMAT相比切向束设置并未显著降低腋窝非计划剂量。
- VMAT可应用于与Z0011试验相似的临床情形,但腋窝中间剂量更高,其毒性临床后果未知。
研究设计与样本
- 治疗计划完成后勾画腋窝I-II水平。
主要发现
- 腋窝I水平V50%:VMAT 2x<90°为71.3 cm3(84%结构体积,p<0.001),VMAT 1x270°为68.8 cm3(81%,p<0.01),3DCRT为60.3 cm3(71%),F-IMRT为60.8 cm3(72%)。
- 腋窝II水平V50%:VMAT 2x<90°为12.3 cm3(12%),VMAT 1x270°为8.9 cm3(9%),3DCRT为4.3 cm3(4%),F-IMRT为4.4 cm3(4%)。
- 高剂量(V90%及以上)各技术间未见临床相关差异。
临床怎么用
- 对于类似Z0011试验情形的全乳放疗患者,VMAT在肿瘤控制方面可替代切向束技术。
- 需注意VMAT增加腋窝I水平中间剂量,其毒性影响尚未明确。
局限性
- 腋窝I-II水平在治疗计划完成后勾画,可能影响剂量评估的准确性。
- 中间腋窝剂量差异的临床毒性后果未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To evaluate dosimetric differences in unintended dose to the lower axilla between 3D-standard (3DCRT), tangential beam forward intensity modulated radiotherapy (F-IMRT) and volumetric modulated arc therapy (VMAT). The objective is to evaluate whether results of clinical trials, such as the ACOSOG-Z011 trial, that evaluated omission of axillary clearance can be extrapolated towards more conformal techniques like VMAT. MATERIALS AND METHODS: Twenty-five consecutive patients treated with whole breast radiotherapy alone (WBRT) using a F-IMRT technique were identified. Three additional plans were created for every patient: one plan using a single 270° arc (VMAT 1x270°), another using two small ≤90° opposing arcs (VMAT 2x < 90°) and thirdly a 3DCRT plan without F-IMRT. Axillary levels I-II were contoured after the treatment plans were made. RESULTS: The volume of the axilla level I that was covered by the 50% isodose (V50%) was significantly higher for VMAT 2x < 90° (71.3 cm3, 84% of structure volume, p < 0.001) and VMAT 1x270° (68.8 cm3, 81%, p < 0.01) compared to 3DCRT (60.3 cm3, 71%) and F-IMRT (60.8 cm3, 72%). The V50% to the axilla level II, however, was low for all techniques: 12.3 cm3 (12%); 8.9 cm3 (9%); 4.3 cm3 (4%); 4.4 cm3 (4%) for VMAT 2x < 90°, VMAT 1x270°, 3DCRT, F-IMRT, respectively. For the higher doses (V90% and above), no clinically relevant differences were seen between the different modalities. CONCLUSION: WBRT treatments with VMAT do not lead to a significant reduction of the unintended axillary dose in comparison with a tangential beam setup. Hence, concerning tumor control, VMAT can be applied to clinical situations similar to the Z0011 trial. The intermediate axillary dose is higher with VMAT, but the clinical consequence of this difference on toxicity is unknown.
引用
- Ahrouch I, Van Gestel D, Koshariuk O, et al. Unintended dose to the lower axilla in adjuvant radiotherapy for breast cancer: Differences between tangential beam and VMAT. Radiother Oncol. 2021. PMID: 34648872. doi:10.1016/j.radonc.2021.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。